B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
ARDX
ArdelyxCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Commercial momentum remains meaningful: Q2 combined product revenue was a company record, IBSRELA demand and prescriptions were strong, XPHOZAH grew, and management cited a cash and investment balance of $281.8 million with profitability targeted for 2027 [#SEC-8K-2026-08-06]. ACCEL provides a longer-duration pipeline option.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -19.0.
What can break
ACCEL enrollment, development, and eventual readout carry clinical and execution risk.
Momentum
3
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.20 · Bull $6.00 · Bear $2.50Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $12.90
Why
Momentum3 · Δ7d +0.5
Value41 · Δ7d 0.0
Sentiment77 · Δ7d -19.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -19.0.
Contradictions & invalidation
- • ACCEL enrollment, development, and eventual readout carry clinical and execution risk.
- • Analyst revision data and consensus surprise data are unavailable, limiting post-earnings validation.
- • The guidance reduction confirms a material near-term access and execution issue for IBSRELA.
Catalyst clock
2026-09-30
Post-Q2 guidance-reset digestion
Lead driver: Sentiment · See AI snapshot
Momentum
3
9% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
-1.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
77
62% active weight
Current posture
7d trendSoftening
Δ7d
-19.0
Δ21d
-19.0
Why this grade
Composite grade C. Momentum 2.6 / Value 41.2 / Sentiment 77.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.01B
Beta
0.56
Shares Out
249.19M
P/E (TTM) · Derived
-15.9
P/S (TTM)
3.72
P/FCF (TTM) · Derived
-56.47
Rev YoY
+23.8%
EPS YoY
-15.2%
Gross Margin
+93.6%
Op Margin
-7.9%
Net Debt
-$56.74M
Current Ratio
3.34
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data